XPO1 inhibitors, Selinexor and Eltanexor showed increased efficacy in SF3B1-mutant (SF3B1 K700E and K666N) MDS patients in phase I/II clinical trial [146]. Here, XPO1 is linked to myelodysplastic syndrome.